


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound represented by formula (1):

Formula 1



wherein

R¹, R² and R⁵ are each independently selected from a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group which may be substituted with one or more halogen atoms and a C₁-C₆ alkoxy group which may be substituted with one or more halogen atoms;

R³ and R⁴ are each independently selected from a hydrogen atom, a halogen atom, -NRfRg, -CONRfRg, -CH=NORe, a C₁-C₆ alkoxy group, a C₁-C₆ alkyl group and -T-(CH₂)_k-V, wherein the alkyl group and the alkoxy group may be substituted with one or more substituents selected from a hydroxyl group, a C₁-C₆ alkoxy group, a halogen atom and -NRfRg;

wherein

Re is selected from a hydrogen atom and C₁-C₆ alkyl,
wherein the alkyl group may be substituted with one to
three substituents selected from a hydroxyl group, a
C₁-C₆ alkoxy group, a halogen atom and -NRhRi,
Rf and Rg are each independently selected from a
hydrogen atom, C₁-C₆ alkyl group and C₁-C₆
alkylcarbonyl group, wherein the alkyl group and the
alkylcarbonyl group may be substituted with one to
three substituents selected from a hydroxyl group, a
C₁-C₆ alkoxy group, a halogen atom and -NRhRi,
Rh and Ri are each independently selected from a
hydrogen atom and C₁-C₆ alkyl group, wherein the alkyl
group may be substituted with one to three
substituents selected from a hydroxyl group, a halogen
atom and a C₁-C₆ alkoxy group, or
Rf and Rg, and Rh and Ri together with a nitrogen atom
to which they are attached may form a 4- to 7-
heterocycle, wherein the heterocycle may be
substituted with a C₁-C₆ alkyl group,
T is an oxygen atom or a single bond; k is an integer
selected from 0 to 4;
V is a 5- to 6-membered heterocyclyl group which may be
substituted with one or more Y³, -NRaRb,

CONRaRb, -OC(=O)NRaRb, -SO₂NRaRb, -N(-Ra)C(=O)ORd, -C(=O)ORD, -

Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORd, -C(=O)ORD, -

S(=O)_m-Rd, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc, -

N(Ra)SO₂Rc, -C(=NRa)NRa'Rb', -C(=NORa)Rc or -

C(=O)Rc;

R⁶ and R⁷ are each independently selected from a hydrogen atom and a halogen atom;

Z¹ and Z² are each independently selected from a hydrogen atom, a hydroxyl group and -O(CHR¹¹)OC(=O)R¹²;


wherein

R¹¹ is a hydrogen atom or a C₁-C₆ alkyl group;

R¹² is a pyrrolidinyl group, a piperidinyl group, a morpholinyl group, a piperazinyl group, an amino C₁-C₆ alkyl group, a mono- or di(C₁-C₆ alkyl)amino C₁-C₆ alkyl group, an amino C₁-C₆ alkylamino group or a mono- or di(C₁-C₆ alkyl)-amino C₁-C₆ alkylamino group;

Q is a group of

Formula 2



wherein

G¹ is C-Y²-O-N,

~~ring A is a benzene ring or a 5 to 6 membered unsaturated heterocycle; a nitrogen atom present in the heterocycle may be an N oxide; and the ring A may be substituted with one to three same or different substituents W;~~

~~Y¹ and Y² are each is independently selected from a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group, a C₂-C₆ alkenyl group, a C₁-C₆ alkoxy group, a mono- or dihydroxy C₁-C₆ alkyl group, a C₁-C₆ alkoxy C₁-C₆ alkoxy group, an amino C₁-C₆ alkoxy group, a (C₁-C₆ alkyl)amino C₁-C₆ alkoxy group, a di(C₁-C₆ alkyl)amino C₁-C₆ alkoxy group, a C₁-C₆ alkoxy C₁-C₆ alkyl group, an amino C₁-C₆ alkyl group, a (C₁-C₆ alkyl)amino C₁-C₆ alkyl group, a di(C₁-C₆ alkyl)amino C₁-C₆ alkyl group, an amino group, a (C₁-C₆ alkyl)amino group and a di(C₁-C₆ alkyl)amino group;~~

Wherein

Q is optionally substituted by at least one substituents W, where W is a halogen atom, a nitro group, a cyano group, a hydroxyl group, -NRaRb, -N=C(-Rc)NRaRb, -CONRaRb, -OC(=O)NRaRb, -SO₂NRaRb, -N(-Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORD, -N[C(=O)ORD][C(=O)ORD'], -C(=O)ORD, -S(=O)_m-Rd, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc, -

N [C(=O)Rc] [C(=O)Rc'] , -N(-Ra)SO₂Rc, -N(SO₂Rc) (SO₂Rc') , -C(=NORd)NRa'Rb' , -C(=NRA)NRa'Rb' , -C(=NORa)Rc, -C(=O)Rc, a C₁-C₆ alkyl group which may be substituted with one or more Y³, a C₂-C₇ alkenyl group which may be substituted with one or more Y³, a C₂-C₇ alkynyl group which may be substituted with one or more Y³, an aryl group which may be substituted with one or more Y³ or a heteroaryl group which may be substituted with one or more Y³;

Ra, Ra', Rb, Rb', Rc, Rc', Rd and Rd' are each independently selected from a hydrogen atom, a C₁-C₁₀ alkyl group, a C₃-C₈ cycloalkyl group, a C₂-C₈ alkenyl group, a C₂-C₈ alkynyl group, -[(C₁-C₆ alkylene)-O]_n-(C₁-C₃ alkyl), a tetrahydropyranyl group, a tetrahydrofuranyl group, an aryl group, a heteroaryl group, and a nitrogen-containing heterocyclyl group (wherein the nitrogen atom on the heterocyclyl group may be substituted with a C₁-C₃ alkyl group); or Ra and Rb, Ra' and Rb', Ra and Rd, Ra and Ra', Ra and Rc, Rc and Rc', and Rd and Ra' may form a saturated or unsaturated 5- to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups and the heterocycle may be substituted with a C₁-C₆ alkyl group;

R_a, R_{a'}, R_b, R_{b'}, R_c, R_{c'}, R_d and R_{d'} each may be substituted with one to three same or different substituents selected from Y³;

m is an integer selected from 0 to 2;

n is an integer selected from 1 to 4;

Y³ is a halogen atom, NR_xR_y, C(=O)OR_z, C(=O)R_z, OR_z, C(=O)NR_xR_y, OC(=O)NR_xR_y, SO₂NR_xR_y, N(R_x)C(=O)NR_{x'}R_{y'}, N(R_x)C(=O)OR_z, S R_z, SO R_z, SO₂ R_z, OC(=O)R_z, N(R_x)C(=O)R_z, C(=NOR_z)NR_{x'}R_{y'}, C(=NOR_x)NR_{x'}R_{y'}, C(=NOR_x)R_z, [O-(C₁-C₆ alkylene)]_n-O(C₁-C₆ alkyl), N(R_x)-(C₁-C₆ alkylene)-O(C₁-C₆ alkyl), C(=O)R_z, a C₁-C₆ alkyl group, a C₂-C₈ alkenyl group, a C₂-C₈ alkynyl group, an aryl group or a heteroaryl group;

R_x, R_{x'}, R_y, R_{y'} and R_z are each independently selected from a hydrogen atom and a C₁-C₄ alkyl group;


R_x and R_y, R_x and R_{x'}, R_x and R_z, and R_z and R_{x'} may form a saturated or unsaturated 5 to 6 membered heterocycle by ring closing at the bonding position of each of these two groups;


a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. (Original) The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein R² is selected from a halogen atom, a trifluoromethyl group and a trifluoromethoxy group.

3. (Currently Amended) The compound of claim + 2,
a pharmaceutically acceptable salt thereof or a prodrug
thereof, wherein Q is a group of the formula selected from
Formula 3





which may be substituted with one to three same or different substituents W.

Claims 4-5 (Cancelled)

6. (Previously Presented) The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein

R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from a hydrogen atom, a chlorine atom, a fluorine atom, a bromine atom and a trifluoromethyl group;

R^6 and R^7 are hydrogen atoms; and

Z^1 and Z^2 are each independently selected from a hydrogen atom, and a hydroxyl group.

7. (Previously Presented) The compound of claim 1, a pharmaceutically acceptable salt thereof or a prodrug thereof,

wherein

R^3 and R^4 are each independently selected from a hydrogen atom, a halogen atom, a C_1-C_6 alkyl group which may be substituted with one or more hydroxyl

groups or halogen atoms, a C₁-C₆ alkoxy group which may be substituted with one or more halogen atoms, and -T-(CH₂)_k-V;

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be substituted with one or more substituents selected from a hydroxy group, an amino group, C₁-C₆ alkyl group, C₁-C₆ alkoxy group and C₁-C₆ alkylcarbonyl group.

8. (Previously Presented) A compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 which has Raf inhibiting effect and angiogenesis inhibiting effect and is used for treating cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes.

9. (Previously Presented) A pharmaceutical composition comprising a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 as an active ingredient.

10. (Previously Presented) An Raf inhibitor or an angiogenesis inhibitor comprising a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 as an active ingredient.

11. (Previously Presented) A preventive or therapeutic agent for a disease selected from cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes which comprises a compound, a pharmaceutically acceptable salt thereof or a prodrug thereof of claim 1 as an active ingredient.

Claims 12-13 (Cancelled)